Cadila Healthcare can begin a new bull run on technical levels......analysis is also backed by news of Virafin(an antiviral produced by Cadila Healthcare) being given emergency approval for treatment of moderate COVID-19 patients.
Volume has also increased drastically.
Cadila has also given closing above a trendline which was previously acting as resistance for the price to move up.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.